• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors

    6/28/21 8:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CABA alert in real time by email

    Dr. Brun's early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Cabaletta's rapidly emerging pipeline

    PHILADELPHIA, June 28, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointment of veteran biopharmaceutical leader, Scott Brun, M.D., to its Board of Directors. Dr. Brun has over 20 years of wide-ranging drug development and business development experience, including his time as Vice President and Head of Pharmaceutical Development at AbbVie Inc., or AbbVie, and the predecessor company, Abbott Laboratories, and Head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities.

    "Scott is an accomplished physician and executive whose pharmaceutical perspective on early and late-stage clinical development, strategic partnership and investment experience, including particular expertise in clinical development of products in the autoimmune, neurologic, and renal disease therapeutic areas, aligns well with our rapidly advancing pipeline. His expertise will be particularly valuable to Cabaletta as we advance our lead program, DSG3-CAART, in mucosal pemphigus vulgaris," said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta. "We welcome him to the Board of Directors and look forward to his contributions to our strategic and operational objectives as we seek to increase shareholder value."

    Dr. Brun spent two decades at AbbVie and Abbott Laboratories, the predecessor company, where he was most recently Vice President of Scientific Affairs and Head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities within AbbVie's R&D therapeutic areas as well as technology platforms of interest. Previously, Dr. Brun served as Vice President and Head of Pharmaceutical Development. During his tenure, Dr. Brun oversaw a global organization with responsibilities for AbbVie's entire portfolio of early and late-stage clinical pre-registration pipeline compounds as well as marketed compounds within oncology, neurology, immunology, renal, infectious disease, and women's and men's health therapeutic areas. Earlier in his career, he held positions of increasing leadership responsibility in drug development within the R&D organization at Abbott Laboratories. Dr. Brun is currently President at Gold Mast Consulting, LLC, an advisory firm he founded to provide technical advice and strategic guidance related to biopharmaceutical research and development, pipeline portfolio management, commercialization of new therapeutics and strategic communications related to R&D activities. Dr. Brun received his B.S. in Biochemistry from the University of Illinois at Urbana-Champaign and earned his M.D. from the Johns Hopkins University School of Medicine. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School.

    "Based on a robust and elegant scientific platform, Cabaletta has the potential to revolutionize the treatment landscape for autoimmune disease and I look forward to contributing to the Board of Directors and partnering with leadership team as they seek to achieve their mission of providing a deep and durable treatment for patients with B cell-mediated autoimmune diseases," said Scott Brun, M.D.

    Dr. Brun will become a member of the Audit Committee and the Nominating and Corporate Governance Committee. Dr. Brun will succeed Brian Daniels, M.D., who resigned from the Board of Directors effective June 24, 2021, and subsequently joined the Scientific Advisory Board. Dr. Daniels has served on Cabaletta's Board of Directors since October 2018.

    "Speaking for the entire leadership team and his colleagues on the Board of Directors at Cabaletta, I want to thank Dr. Daniels for his keen insights and thoughtful, probing questions over the last three years and his service to the Board of Directors. His advice and counsel proved invaluable. We are fortunate to be able to continue our engagement with Dr. Daniels moving forward as a member of our Scientific Advisory Board," continued Dr. Nichtberger.

    About Cabaletta Bio

    Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta's proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company's lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please see www.clinicaltrials.gov. The Company's lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" of Cabaletta within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding the company's business plans and objectives; expectations regarding the progress and results of its DesCAARTes™ Phase 1 trial; the effectiveness and timing of product candidates that Cabaletta may develop, including in collaboration with academic partners; statements regarding regulatory filings regarding its development programs; and the anticipated contribution of the members of our board of directors and our executives to our operations and progress.

    Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: Cabaletta's ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its clinical trials of DSG3-CAART; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to the impact of public health epidemics affecting countries or regions in which we have operations or do business, such as COVID-19; and the risk that the initial or interim results of clinical studies will not be predictive of future results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Cabaletta's most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.

    Contacts:

    Anup Marda

    Chief Financial Officer

    [email protected]

    Sarah McCabe

    Stern Investor Relations, Inc.

    212-362-1200

    [email protected]

     



    Primary Logo

    Get the next $CABA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CABA

    DatePrice TargetRatingAnalyst
    12/20/2024$15.00 → $6.00Outperform → In-line
    Evercore ISI
    12/19/2024$12.00 → $6.00Overweight → Equal Weight
    Wells Fargo
    10/10/2024$10.00Buy
    UBS
    2/5/2024$36.00Buy
    Jefferies
    11/29/2023$38.00Outperform
    William Blair
    10/24/2023$40.00Overweight
    Cantor Fitzgerald
    10/19/2023$31.00Buy
    Stifel
    9/5/2023$22.00Buy
    Citigroup
    More analyst ratings

    $CABA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Simon Mark

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      6/9/25 8:28:01 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Brun Scott C.

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      6/9/25 8:22:15 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Bollard Catherine

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      6/9/25 8:20:03 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cabaletta Bio downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Cabaletta Bio from Outperform to In-line and set a new price target of $6.00 from $15.00 previously

      12/20/24 7:29:05 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Cabaletta Bio from Overweight to Equal Weight and set a new price target of $6.00 from $12.00 previously

      12/19/24 7:31:17 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Cabaletta Bio with a new price target

      UBS initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $10.00

      10/10/24 7:27:43 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cabaletta Bio Announces Pricing of Public Offering of Securities

      PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 10,800,000 shares of its common stock and accom

      6/11/25 9:54:40 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Announces Proposed Public Offering of Securities

      PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in li

      6/11/25 6:15:28 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

      – 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients – – All SLE patients without nephropathy achieved definition of remission in SLE (DORIS) as of the latest follow-up, and all 7 SLE and LN patients experienced SLEDAI-2K reductions, while off all immunomodulators and steroids – – Both scleroderma patients demonstrated clinically compelling mRSS improvement after discontinuation of all immunomodulators and steroids – – In 18 patients with follow-up of 4 weeks or more, 94% had either no CRS or Grade 1

      6/11/25 6:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Cabaletta Bio Inc.

      SCHEDULE 13G - Cabaletta Bio, Inc. (0001759138) (Subject)

      6/20/25 5:22:59 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Cabaletta Bio Inc.

      8-K - Cabaletta Bio, Inc. (0001759138) (Filer)

      6/12/25 6:05:29 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Cabaletta Bio Inc.

      424B5 - Cabaletta Bio, Inc. (0001759138) (Filer)

      6/12/25 6:03:33 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care